FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Spectrum Given Complete Response on Rolontis

[ Price : $8.95]

FDA sends Spectrum Pharmaceuticals a complete response letter on its BLA for Rolontis (eflapegrastim), citing deficiencies related...

Boston Scientific Trial on Pulmonary Embolism Therapy

[ Price : $8.95]

Boston Scientific begins enrolling in the HI-PEITHO clinical trial to compare its EkoSonic Endovascular System in combination with...

Academics Challenge FDA Suicidality Drug Warning

[ Price : $8.95]

Researchers call on FDA to reconsider class suicide risk warnings for all epilepsy drugs.

Apexigen Orphan Status for Sarcoma Therapy

[ Price : $8.95]

FDA grants Apexigen an orphan drug designation for APX005M (sotigalimab) for treating soft tissue sarcoma.

FDA Touts Use of Real-World Evidence in Prograf Approval

[ Price : $8.95]

Three FDA officials say the recent approval of Astellas Prograf for a new indication demonstrates that real-world data observation...

FDA Complete Response Letter for Ardelyx Tenapanor NDA

[ Price : $8.95]

An FDA complete response letter says an Ardelyx NDA for tenapanor did not show sufficient treatment effect to be approved.

Workshop on Pediatric Complex Trial Designs

[ Price : $8.95]

Federal Register notice: FDA announces a public workshop entitled Advancing the Development of Pediatric Therapeutics Complex Inn...

FDA Faulted for Lax Device Issue Follow-up

[ Price : $8.95]

Pro Publica details the cases of several people harmed by Medtronics HeartWare ventricular assist device and says FDA relied too m...

Pillar Biosciences PMA Approved for Diagnostic

[ Price : $8.95]

FDA approves a Pillar Biosciences PMA for its oncoReveal Dx Lung and Colon Cancer Assay, a next-generation sequencing tissue-based...

FDA Accepts Keytruda sBLA, Sets Priority Review

[ Price : $8.95]

FDA accepts a Merck sBLA for a new Keytruda melanoma indication and will conduct a priority review.